MedTrace Logo

Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE

NCT05446285 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 245

Last updated 2022-07-25

No results posted yet for this study

Summary

To provide real world evidence evaluating whether a strategy of early initiation and escalation of disease modifying treatment (DMT) in relapsing-remitting multiple sclerosis (RRMS) affects disease outcome over a 10 year period. Our aim is to provide evidence for clinicians and patients regarding the benefits and risks of early initiation and active escalation of disease modifying treatments (DMTs) in relapsing-remitting multiple sclerosis (RRMS), using real world data.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

OTHER

Clinical assessment

All participants will be invited to attend their local research facility to undergo a physical and questionnaire assessment as well as an MRI. Assessments include: Expanded Disability Status Scale, 9-Hole Peg Test, MRI scan, Patient Reported Outcome Measures (MSIS-29, neuroQOL and PROMIS), Brief International Cognitive Assessment for MS)

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • NHS Greater Glasgow and Clyde

    lead OTHER

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2023-08-31
Completion
2023-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05446285 on ClinicalTrials.gov